12 results about "Genitourinary system" patented technology

Provided is a method for treating conditions and / or symptoms associated therewith selected from the group consisting of androgen deficiency, male infertility, male urogenital or reproductive system infections and / or disorders and combinations thereof, comprising administering to a subject in need a therapeutically effective amount of a composition comprising at least one cannabinoid in a specific amount, at least one terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene carrier, and optionally at least one herbal extract, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and a weight / weight ratio of a total amount of terpenes to a total amount of cannabinoids is from about 0.1:1 to about 1:1, or; wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and a weight / weight ratio of a total amount of terpenes to a total amount cannabinoids is about 0.05:1 to about 1:1.

The present invention provides a mucosa-based non-invasive gene therapy with a recombinant vector. The recombinant region of the recombinant vector comprises a coding sequence of at least one therapeutic gene. The recombinant vector is administered to the respiratory system, the digestive system, the genitourinary system, and the eyes via the mucosa, for preventing and / or treating a disease.

Discloses herein are methods of treating diseases, disorders, or conditions related to the female genitourinary system. Also disclosed are compositions and delivery devices with therapeutic use in the treatment. Specifically, aspects of the disclosure relate to a degradable and biocompatible device that effectively delivers a therapeutic agent to a subject in need thereof comprising at least one of a stem cell or / and an extracellular vesicle derived thereof, wherein the cells are grown in conditioned medium comprising estrogen or were primed with estrogen, or any combination thereof.

Provided are methods for detecting urogenital malignancies in dogs. In some embodiments, the methods include identifying a deletion or single nucleotide substitution within a BRAF gene and / or within a MAP2K1 gene present in or isolated from a biological sample from a. dog, wherein the presence of the deletion or single nucleotide substitution within the BRAF gene and / or within the MAP2K1 gene detects a urogenital malignancy, optionally transitional cell carcinoma / urothelial carcinoma, in the dog. In some embodiments, the deletion is within exon 12 of BRAF gene, optionally within the amino acid sequence KMLNVTAPTPQQL (SEQ ID NO: 3), and / or in within exon 2 or 3 of a M.AP2K1 gene, optionally within the amino acid sequence FLTQKQKVGE (SEQ ID NO: 4).

Prebiotic formulations can modulate the growth and / or activity of microorganisms in the urogenital area. Such prebiotic formulations can comprise isomaltulose along with at least one other prebiotic, such as 1-kestose or lactulose. These microorganisms which are modulated can be directly related to urogenital health, and their modulation can be used for the prevention, control, or treatment of dysbiosis of the urogenital area.

The invention discloses a deep learning and behavior boosting theory-based accurate prediction system for a urogenital system infection risk of SGLT2 inhibitor hypoglycemic drugs. According to the invention, through the innovative structural design of the deep learning risk prediction module, the individualized accurate prediction of the SGLT2 inhibitor hypoglycemic drug related urogenital infection risk is realized. The module adopts a hybrid neural network of a Transform encoder and a gating circulation unit, can process multi-source clinical data of a patient at the same time, not only identifies deep association between static characteristics such as demostatistics and medical history and infection risks, but also captures fluctuation rules of dynamic sequences such as laboratory inspection indexes along with time. The deep mining capability of a high-dimensional complex data mode breaks through the limitation that a traditional scoring tool depends on limited indexes and fixed weights, differentiated risk levels can be output according to the unique clinical trajectory of each patient, and an accurate decision basis is provided for subsequent intervention.

The invention relates to the technical field of cell staining, in particular to a staining solution and a staining method for a urogenital system sample. According to the invention, two dyes with different properties, namely an acid dye and a basic dye, are mixed to prepare a rapid staining solution, and the rapid staining solution can be used for rapidly staining white blood cell nuclei in a sample into blue-green and cytoplasm is not colored through wet sheet staining; cell nuclei of epithelial cells are dyed into dark blue and cytoplasm is dyed into red; live trichomonad is not dyed, and dead trichomonad is dyed into red; therefore, the visible components can be clearly and accurately distinguished. The dyed epithelial cells, leukocytes, trichomonad, candida and the like are clear in structure and obvious in morphological color difference, and AI image analysis is combined, so that the trichomonad identification accuracy can be improved, the instrument trichomonad auditing rate is eliminated, and automatic interpretation is completely realized.

1. The name of the design product: urogenital system therapeutic instrument. 2. The use of the design product: urogenital system therapeutic instrument. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best shows the design points: perspective view. 5. The design claimed contains color.

A method of treating human or animal tissue, the method comprising the step of: i. directing a stream of an aqueous liquid comprising gas bubbles excited by acoustic energy towards a wound or anatomical pocket in human or animal tissue, or towards an anatomical space or potential space in human or animal tissue, or towards soft or hard tissue in an oral cavity or elsewhere in the human or animal body, or towards tissue in a nasal cavity, or towards tissue associated with sinuses, eye, ear, digestive and genito-urinary systems, thereby to treat the human or animal tissue with the stream. The output stream can clean a wound in human or animal tissue, and can treat the wound by healing the wound, for example by stimulating fibroblasts in the wound tissue and causing, promoting or enhancing re-epithelialisation of epidermal tissue in the wound.

The invention relates to a hypocrellin 2-site amino substituted derivative (formula I) or ethylenediamine substituted derivative (formula II and formula III) as a photodynamic drug for treating the following tumors: esophageal cancer, gastric cancer, lung cancer, liver cancer, bile duct cancer and colon cancer cells related to digestive tract tumors; brain cancer, head and neck cancer, tongue cancer, nasal cancer, oral cancer and brain glioma cells related to head, neck and face tumors; basal cell carcinoma, squamous skin carcinoma, skin T cell lymphoma and melanoma cells related to skin tumors; prostate cancer and bladder cancer cells related to genitourinary system tumors. Meanwhile, the derivative can locate the position of a tumor tissue through self-fluorescence and is used for fluorescence-guided tumor operation excision.

A method for treating the gastrointestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

A system and method for treating anorectal and / or genitourinary dysfunction includes implanting, in a minimally invasive manner, an electro-medical device for stimulation of two or more anatomical or histological structures of the anorectal region and / or genitourinary region. Electrodes operably connected to the device are positioned proximate the target anatomical or histological structures. The device provides either the same or different stimulation algorithms to each anatomical or histological structure, which may be the same or different. The varied stimulation parameters, such as pulse width, pulse amplitude, and pulse frequency, are defined such that after an application of the electrical pulses, an abdominal leak pressure, an abdominal leak volume, or a urine volume increases or a number of incontinent episodes or a mean incontinence volume per episode decreases relative to said parameters prior to the application of the electrical pulses.